{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:22:08Z","timestamp":1789590128226,"version":"build-2803163510"},"reference-count":40,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Recent years have provided numerous reports on the mechanisms of action of psychiatric medications (antidepressants, antipsychotics, mood stabilizers, and antidementia drugs) that directly inhibit the growth of cancer cells, as well as on their indirect effects on the psyche and immune system, and their supportive effects on chemotherapeutic agents. The mechanisms of the anticancer activity of psychiatric drugs include inhibition of dopamine and N-methyl-D-aspartate receptors that work via signaling pathways (PI3K\/AKT\/mTOR\/NF-\u03baB, ERK, Wnt\/\u00df-catenin, and bcl2), metabolic pathways (ornithine decarboxylase, intracellular cholesterol transport, lysosomal enzymes, and glycolysis), autophagy, Ca2+-dependent signaling cascades, and various other proteins (actin-related protein complex, sirtuin 1, p21, p53, etc.). The anticancer potential of psychiatric drugs seems to be extremely broad, and the most extensive anticancer literature has been reported on antidepressants (fluoxetine, amitriptyline, imipramine, mirtazapine, and St John\u2019s Wort) and antipsychotics (chlorpromazine, pimozide, thioridazine, and trifluoperazine). Among mood stabilizers, lithium and valproates have the largest body of literature. Among antidementia drugs, memantine has documented anticancer effects, while there is limited evidence for galantamine. Of the new psychiatric substances, the antipsychotic drug brexpiprazole and the antidepressant vortioxetine have a very interesting body of literature regarding glioblastoma, based on in vitro and in vivo animal survival studies. Their use in brain tumors and metastases is particularly compelling, as these substances readily cross the blood\u2013brain barrier (BBB). Moreover, the synergistic effect of psychiatric drugs with traditional cancer treatment seems to be extremely important in the fight against chemo- and radio-resistance of tumors. Although there are some studies describing the possible carcinogenic effects of psychiatric drugs in animals, the anticancer effect seems to be extremely significant, especially in combination treatment with radio\/chemotherapy. The emerging evidence supporting the anticancer properties of psychiatric drugs presents an exciting frontier in oncology. The anticancer properties of psychiatric drugs may prove particularly useful in the period between chemotherapy and radiotherapy sessions to maintain the tumor-inhibitory effect. While further research is necessary to elucidate the mechanisms, clinical implications, dose-dependence of the effect, and clear guidelines for the use of psychiatric medications in cancer therapy, the potential for these commonly prescribed medications to contribute to cancer treatment enhances their value in the management of patients facing the dual challenges of mental health and cancer.<\/jats:p>","DOI":"10.3390\/jcm14176003","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:26:31Z","timestamp":1756189591000},"page":"6003","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Future of Oncology in Psychiatric Medications"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7021-5133","authenticated-orcid":false,"given":"Napoleon","family":"Waszkiewicz","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Medical University of Bia\u0142ystok, 15-272 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.21037\/apm-22-1287","article-title":"Is every psychiatrist an oncology psychiatrist?\u2014Special needs for special populations: A scoping review","volume":"13","author":"Steinhoff","year":"2024","journal-title":"Ann. Palliat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","article-title":"Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies","volume":"12","author":"Mitchell","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mehnert-Theuerkauf, A., Hufeld, J.M., Esser, P., Goerling, U., Hermann, M., Zimmermann, T., Reuter, H., and Ernst, J. (2023). Prevalence of mental disorders, psychosocial distress, and perceived need for psychosocial support in cancer patients and their relatives stratified by biopsychosocial factors: Rationale, study design, and methods of a prospective multi-center observational cohort study (LUPE study). Front. Psychol., 14.","DOI":"10.3389\/fpsyg.2023.1125545"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ge, M.W., Sheng, J., Shen, L.T., Hu, F.H., Jia, Y.J., Ur-Rehman, A., Li, W., Lan, J.Z., Liu, P., and Chen, H.L. (2025). Global Prevalence of Mental Health Problems Among Cancer Survivors: A Meta-Analysis From 31 Countries. Psychooncology, 34.","DOI":"10.1002\/pon.70077"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41591-022-01740-3","article-title":"Cumulative burden of psychiatric disorders and self-harm across 26 adult cancers","volume":"28","author":"Chang","year":"2022","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4143\/crt.2013.45.3.226","article-title":"Psychosocial impact of cancer patients on their family members","volume":"45","author":"Lim","year":"2013","journal-title":"Cancer Res. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/cncr.22980","article-title":"Psychiatric disorders in advanced cancer","volume":"110","author":"Miovic","year":"2007","journal-title":"Cancer"},{"key":"ref_8","first-page":"299","article-title":"The desire for death in the setting of terminal illness: A case discussion","volume":"8","author":"Guy","year":"2006","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.schres.2022.07.008","article-title":"Cancer rates and mortality in people with severe mental illness: Further evidence of lack of parity","volume":"246","author":"Launders","year":"2022","journal-title":"Schizophr. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1192\/bja.2021.9","article-title":"Psychosocial stress and immunosuppression in cancer: What can we learn from new research?","volume":"27","author":"Singh","year":"2021","journal-title":"BJPsych Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(07)61238-0","article-title":"No health without mental health","volume":"370","author":"Prince","year":"2007","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/87551225211073942","article-title":"Potential Drug Interactions Between Psychotropics and Intravenous Chemotherapeutics Used by Patients with Cancer","volume":"38","author":"Camargo","year":"2022","journal-title":"J. Pharm. Technol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11920-024-01570-9","article-title":"The Challenging Problems of Cancer and Serious Mental Illness","volume":"27","author":"Grassi","year":"2025","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Anghel, T., Melania, B.L., Costea, I., Albai, O., Marinca, A., Levai, C.M., and Hogea, L.M. (2025). Review of Psychological Interventions in Oncology: Current Trends and Future Directions. Medicina, 61.","DOI":"10.3390\/medicina61020279"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"172732","DOI":"10.1016\/j.ejphar.2019.172732","article-title":"Off-label uses of drugs for depression","volume":"865","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Fuentes, A.V., Pineda, M.D., and Venkata, K.C.N. (2018). Comprehension of Top 200 Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice. Pharmacy, 6.","DOI":"10.3390\/pharmacy6020043"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2045125320970325","DOI":"10.1177\/2045125320970325","article-title":"May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance","volume":"10","author":"Fava","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Vlachos, N., Lampros, M., Voulgaris, S., and Alexiou, G.A. (2021). Repurposing Antipsychotics for Cancer Treatment. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121785"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lampros, M., Vlachos, N., Lianos, G.D., Bali, C., and Alexiou, G.A. (2025). Editorial: Drug repurposing for cancer treatment: Current and future directions. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1550672"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Brown, J.S. (2022). Treatment of cancer with antipsychotic medications: Pushing the boundaries of schizophrenia and cancer. Neurosci. Biobehav. Rev., 141.","DOI":"10.1016\/j.neubiorev.2022.104809"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Varalda, M., Antona, A., Bettio, V., Roy, K., Vachamaram, A., Yellenki, V., Massarotti, A., Baldanzi, G., and Capello, D. (2020). Psychotropic Drugs Show Anticancer Activity by Disrupting Mitochondrial and Lysosomal Function. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.562196"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/d41586-025-01569-z","article-title":"Brain drugs can now cross the once impenetrable blood-brain barrier","volume":"641","author":"Abbott","year":"2025","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41591-024-03224-y","article-title":"High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity","volume":"30","author":"Lee","year":"2024","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Chang, X., Huang, Y., and He, D. (2023). The application of antidepressant drugs in cancer treatment. Biomed. Pharmacother., 157.","DOI":"10.1016\/j.biopha.2022.113985"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.euroneuro.2015.04.010","article-title":"Anti-depressant therapy and cancer risk: A nested case-control study","volume":"25","author":"Boursi","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14737140.2022.1987221","article-title":"Repurposing antipsychotic drugs for cancer treatment: Current evidence and future perspectives","volume":"22","author":"Lianos","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.neo.2017.10.002","article-title":"Role of Dopamine Receptors in the Anticancer Activity of ONC201","volume":"20","author":"Kline","year":"2018","journal-title":"Neoplasia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/0004867415582231","article-title":"Carcinogenicity of psychotropic drugs: A systematic review of US Food and Drug Administration-required preclinical in vivo studies","volume":"49","author":"Amerio","year":"2015","journal-title":"Aust. New Zealand J. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Villegas-V\u00e1zquez, E.Y., Quintas-Granados, L.I., Cort\u00e9s, H., Gonz\u00e1lez-Del Carmen, M., Leyva-G\u00f3mez, G., Rodr\u00edguez-Morales, M., Bustamante-Montes, L.P., Silva-Adaya, D., P\u00e9rez-Plasencia, C., and Jacobo-Herrera, N. (2023). Lithium: A Promising Anticancer Agent. Life, 13.","DOI":"10.3390\/life13020537"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Aron, L., Ngian, Z.K., Qiu, C., Choi, J., Liang, M., Drake, D.M., Hamplova, S.E., Lacey, E.K., Roche, P., and Yuan, M. (2025). Lithium deficiency and the onset of Alzheimer\u2019s disease. Nature.","DOI":"10.1038\/s41586-025-09335-x"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.drudis.2021.10.019","article-title":"Repurposing antidepressants for anticancer drug discovery","volume":"27","author":"Song","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Chen, V.C., Hsu, T.C., Lin, C.F., Huang, J.Y., Chen, Y.L., Tzang, B.S., and McIntyre, R.S. (2022). Association of Risperidone with Gastric Cancer: Triangulation Method from Cell Study, Animal Study, and Cohort Study. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.846455"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"216125","DOI":"10.1016\/j.canlet.2023.216125","article-title":"Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors?","volume":"560","author":"Natale","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3892\/ijo.2022.5370","article-title":"Antitumor effect of memantine is related to the formation of the splicing isoform of GLG1, a decoy FGF-binding protein","volume":"61","author":"Yamaguchi","year":"2022","journal-title":"Int. J. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Liu, C.T., Yang, C.C., Chien, W.C., Chung, C.H., Tsai, C.S., Tsai, Y.T., Lin, C.Y., Lin, Y.C., Chen, Y.S., and Tzeng, N.S. (2022). Association between long-term usage of acetylcholinesterase inhibitors and lung cancer in the elderly: A nationwide cohort study. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-06377-3"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3897\/pharmacia.70.e109841","article-title":"Cytotoxic activity of Galantamine hydrobromide against HeLa cell line","volume":"70","author":"Obreshkova","year":"2023","journal-title":"Pharmacia"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ma, L., Tan, E.C.K., Goudey, B., Jin, L., and Pan, Y. (2025). Unraveling the bidirectional link between cancer and dementia and the impact of cancer therapies on dementia risk: A systematic review and meta-analysis. Alzheimer\u2019s Dement., 21.","DOI":"10.1002\/alz.14540"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Pace, A., Lombardi, G., Villani, V., Benincasa, D., Abbruzzese, C., Cestonaro, I., Corr\u00e0, M., Padovan, M., Cerretti, G., and Caccese, M. (2023). Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1320710"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.mehy.2012.03.026","article-title":"Antipsychotic drugs: Pro-cancer or anti-cancer? A systematic review","volume":"79","author":"Fond","year":"2012","journal-title":"Med. Hypotheses"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/6003\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:32:33Z","timestamp":1760034753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/6003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":40,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["jcm14176003"],"URL":"https:\/\/doi.org\/10.3390\/jcm14176003","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]}}}